Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC).
INTRODUCTION:Non-invasive mutation testing using circulating tumour DNA (ctDNA) is an attractive premise. This could enable patients without available tumour sample to access more treatment options. MATERIALS & METHODS:Peripheral blood and matched tumours were analysed from 45 NSCLC patients. We...
Main Authors: | James L Sherwood, Claire Corcoran, Helen Brown, Alan D Sharpe, Milena Musilova, Alexander Kohlmann |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4769175?pdf=render |
Similar Items
-
Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA)
by: Pauline Gilson, et al.
Published: (2021-03-01) -
Impact of Circulating Tumor DNA (ctDNA) in Patients with Gastrointestinal Malignancies
Published: (2020) -
Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report
by: Leslie Calapre, et al.
Published: (2019-11-01) -
Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.
by: Chengjuan Zhang, et al.
Published: (2017-01-01) -
Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer
by: Yidong Zhou, et al.
Published: (2019-05-01)